U.S. Pharmacist eNewsletter
February 2022

First Participant Dosed in Phase I Study of mRNA EBV Vaccine

In a recent press release, the manufacturer, Moderna, announced the first participant has been dosed in the phase I study, known as Eclipse, for the novel vaccine, mRNA-1189, the company's Epstein-Barr virus (EBV) vaccine candidate. Moderna's vaccine candidate against EBV is being developed to prevent EBV-induced infectious mononucleosis and, potentially, EBV infection. Read more.


Study: Effectiveness of COVID-19 Vaccines Over 9 Months in NC
A recent study utilized surveillance data to evaluate the long-term effectiveness of Pfizer, Moderna, and Johnson & Johnson COVID-19 vaccines in preventing SARS-CoV-2 infection, hospitalizations, and deaths. This large study found that the three vaccines, especially the Pfizer and Moderna mRNA vaccines, provided a high degree of protection against severe illness at least 6 months after vaccination. Read more.

Study Explores Homologous and Heterologous COVID-19 Booster Vaccinations
In a recent publication in The New England Journal of Medicine, researchers published data from the ongoing National Institute of Health (NIH)-sponsored trial that resulted in the FDA authorizing the mix-and-match strategy for COVID-19 vaccine boosters last fall. Learn more about what researchers concluded with both homologous and heterologous booster vaccines in the clinical study.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App